{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-121675","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.310081+00:00","generated_at":"2026-06-07T20:46:36.682031+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cyclacel receives Nasdaq notice for late Q3 10-Q filing; 60 days to submit compliance plan","bullets":["Notice received Nov 21, 2023 for failure to timely file Quarterly Report for period ended Sep 30, 2023.","Company has 60 calendar days (to Jan 20, 2024) to submit a plan to regain compliance.","If accepted, Nasdaq may grant up to 180 days (to May 20, 2024) to file the overdue report.","No immediate effect on listing, but no assurance compliance can be regained.","Common stock (CYCC) and preferred stock (CYCCP) listed on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-121675","json":"https://secwatch.observer/filing/0001104659-23-121675.json","markdown":"https://secwatch.observer/filing/0001104659-23-121675.md","text":"https://secwatch.observer/filing/0001104659-23-121675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923121675/0001104659-23-121675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923121675/tm2331442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:46:36.682031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"daed55bb53018eec73f426d391b0822ea860e20f","claim":"Bio Green Med Solution, Inc. received a nasdaq noncompliance notice notice regarding late filing.","evidence_excerpt":"November 21, 2023, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s continued listing standards because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”). Under Nasdaq rules, the Company now has 60 calendar days (or until January 20, 2024) to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar da","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923121675/0001104659-23-121675-index.htm","confidence":0.93,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"late filing"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}